Mistrello G, Bassi L
J Immunopharmacol. 1984;6(1-2):25-41. doi: 10.3109/08923978409026456.
L-alanosine is an antitumor compound which has recently entered clinical trials. Single i.p. doses of this drug inhibit antibody production to thymus-dependent and thymus-independent antigens as well as delayed hypersensitivity to SRBC in mice. Moreover, the in vitro lymphoproliferative responses of splenocytes to Concanavalin A and bacterial Lipopolysaccharides are also affected when the drug is added upon setting up the cultures. On the other hand, in vivo treatment with L-alanosine does not impair spleen natural killer (NK) activity. The results are discussed in an effort to characterize the immuno-suppressive activity of L-alanosine.
L-丙氨菌素是一种最近已进入临床试验的抗肿瘤化合物。给小鼠单次腹腔注射该药物可抑制其对胸腺依赖性和非胸腺依赖性抗原产生抗体，以及抑制对绵羊红细胞的迟发型超敏反应。此外，在培养开始时加入该药物，也会影响脾细胞对刀豆球蛋白A和细菌脂多糖的体外淋巴细胞增殖反应。另一方面，用L-丙氨菌素进行体内治疗不会损害脾脏自然杀伤（NK）活性。本文对这些结果进行了讨论，以试图阐明L-丙氨菌素的免疫抑制活性。
